This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries. In 2015, Zimmer Holdings, Inc. (the legacy company) acquired Biomet, Inc. to form a new consolidated company.
Will Pricing Pressure Hurt Zimmer Biomet (ZBH) Q1 Earnings?
by Zacks Equity Research
With Zimmer Biomet (ZBH) focusing solely on this restructuring initiative, chances are slim for the company to post promising growth performances across its operating segments.
Earnings Preview: Zimmer Biomet (ZBH) Q1 Earnings Expected to Decline
by Zacks Equity Research
Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zimmer Biomet's FDA 510(k) Nod Widens Robotic Offerings
by Zacks Equity Research
With the FDA nod, Zimmer Biomet (ZBH) attains the status of being the first company to boast the 510(k) clearance for Brain, Spine and Knee offerings on a single robotic platform globally.
Zimmer Biomet Solid on Global Prospects Despite Price Pressure
by Zacks Equity Research
Zimmer Biomet (ZBH) has been working to strengthen foothold in emerging markets. However, the company has been facing continued pricing pressure.
RTI Surgical Buys Paradigm Spine, Adds Coflex to Portfolio
by Zacks Equity Research
RTI Surgical's (RTIX) acquisition of Paradigm Spine aligns with the former's goal of expanding its spine portfolio.
Zimmer Biomet (ZBH) Jumps: Stock Rises 6.4%
by Zacks Equity Research
Zimmer Biomet (ZBH) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Zimmer Biomet (ZBH) Q4 Earnings Meet Estimates, Revenues Top
by Zacks Equity Research
Zimmer Biomet (ZBH) sees strength in the Asia Pacific and EMEA regions as well as in the Spine & CMF business in Q4.
Zimmer Biomet (ZBH) Meets Q4 Earnings Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 0.00% and 0.54%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
ZBH & IDXX Q4 Earnings on Feb 1: Here are the Key Predictions
by Zacks Equity Research
The global medical device space is passing through a rewarding phase for a considerable period of time in terms of research and development (R&D) plus regulatory progress.
Medical Products Industry Outlook: Plenty of Upside Left
by Zacks Equity Research
The growing adoption of AI, Medical Mechatronics & Robotics has lent the Medical Products industry a competitive edge in the broader medical market.
Can Zimmer Biomet (ZBH) Grow on Hip Business in Q4 Earnings?
by Zacks Equity Research
Within Hip business, we expect Zimmer Biomet (ZBH) to experience a strong uptick in the Asia-Pacific region.
Zimmer Biomet (ZBH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Zimmer (ZBH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Zimmer Biomet (ZBH) a Great Stock for Value Investors?
by Zacks Equity Research
Let's see if Zimmer Biomet (ZBH) stock is a good choice for value-oriented investors right now from multiple angles.
Zimmer Biomet (ZBH) Thrives on New Projects, APAC Growth
by Zacks Equity Research
Zimmer Biomet (ZBH) is performing well on the back of its two largest commercial projects, namely the Persona Revision system and the Rosa robotics knee application.
Zimmer Biomet Rides on New Operational Plan Amid Several Woes
by Zacks Equity Research
In order to tackle several near-term concerns, Zimmer Biomet (ZBH) of late begins to review its 2018 operating plan to clearly define its go-forward strategies in a number of thrust areas.
Should Value Investors Pick Zimmer Biomet (ZBH) Stock?
by Zacks Equity Research
Is Zimmer Biomet (ZBH) a great pick from the value investor's perspective right now? Read on to know more.
Zimmer (ZBH) Down 7.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights: Comcast, ConocoPhillips, Delta Air Lines, ServiceNow and Zimmer Biomet
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Comcast, ConocoPhillips, Delta Air Lines, ServiceNow and Zimmer Biomet
Top Research Reports for Comcast, ConocoPhillips & Delta Air Lines
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Comcast (CMCSA), ConocoPhillips (COP), and Delta Air Lines (DAL).
Zimmer Biomet (ZBH) Q3 Earnings Top Estimates, Margins Down
by Zacks Equity Research
We are encouraged by Zimmer Biomet's (ZBH) consistent effort in product renovation through research and development.
Zimmer Biomet (ZBH) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 1.87% and 0.11%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Zimmer Biomet (ZBH) This Earnings Season?
by Zacks Equity Research
Focusing on areas like quality correction, supply recovery and product introductions, Zimmer Biomet (ZBH) is expected to see robust top-line numbers at S.E.T. arm in Q3.
Zimmer Biomet (ZBH) Q3 Earnings Preview: What's in the Cards?
by Zacks Equity Research
Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zimmer Biomet (ZBH) Q2 Earnings Top Estimates, Margins Drop
by Zacks Equity Research
The improvement within Zimmer Biomet's (ZBH) global Knee and Hip sales performance and ongoing growth within the Asia Pacific region are encouraging.
Zimmer Biomet (ZBH) Beats on Q2 Earnings & Revenue Estimates
by Zacks Equity Research
Zimmer Biomet (ZBH) rides on strength in Knee and Hip segments in Q2.